Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 15/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.43 |
| ▸ | CALCA | P06881 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4607176 | 0.95 | CALCRL (0.48) | CALCRLCYP3A4RAMP1CALCA | |
| SCHEMBL3960870 | 0.94 | CALCRL (0.49) | CALCRLCYP3A4RAMP1CALCA | |
| SCHEMBL3958339 | 0.92 | CALCRL (0.54) | CALCRLCYP3A4CALCA | |
| SCHEMBL3961964 | 0.92 | CALCRL (0.54) | CALCRLCYP3A4CALCA | |
| SCHEMBL4069296 | 0.91 | CALCRL (0.48) | CALCRLCYP3A4RAMP1CALCA | |
| SCHEMBL3967230 | 0.89 | CALCRL (0.49) | CALCRLCYP3A4RAMP1CALCA | |
| SCHEMBL3964429 | 0.89 | CALCRL (0.54) | CALCRLCYP3A4RAMP1CALCA | |
| SCHEMBL3961202 | 0.87 | CALCRL (0.62) | CALCRLCYP3A4RAMP1CALCA | |
| SCHEMBL3957902 | 0.87 | CALCRL (0.62) | CALCRLCYP3A4RAMP1CALCA | |
| SCHEMBL3962373 | 0.85 | CALCRL (0.56) | CALCRLCYP3A4RAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517674-B1 | PREPARATIONS FOR THE INTRANASAL APPLICATION OF SELECTED CGRP ANTAGONISTS DERIVED FROM AMINO ACIDS AND A METHOD FOR THEIR PRODUCTION | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-04-11 | — | — | EP | claimed |
| EP-1769790-A1 | Preparations for the intranasal application of selected CGRP antagonists derived from amino acids | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-04-04 | — | — | EP | claimed |
| US-20060193786-A1 | Pharmaceutical composition for intranasal administration containing a CGRP antagonist | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | claimed |
| US-20050233980-A1 | CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | claimed |
| US-20050032783-A1 | Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-10 | — | — | US | claimed |
| EP-1207884-B1 | USE OF CGRP ANTAGONISTS AND CGRP RELEASE INHIBITORS FOR CONTROLLING MENOPAUSAL HOT FLASHES | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-11-03 | — | — | EP | claimed |
| US-20040076587-A1 | Pharmaceutical composition for intranasal administration containing a CGRP antagonist | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-04-22 | — | — | US | claimed |
| US-6521609-B1 | Using such as amino acid derivatives or serotonin receptor agonists; side effect reduction | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-02-18 | — | — | US | claimed |
| EP-1517674-B1 | PREPARATIONS FOR THE INTRANASAL APPLICATION OF SELECTED CGRP ANTAGONISTS DERIVED FROM AMINO ACIDS AND A METHOD FOR THEIR PRODUCTION | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-04-11 | — | — | EP | disclosed |
| EP-1769790-A1 | Preparations for the intranasal application of selected CGRP antagonists derived from amino acids | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-04-04 | — | — | EP | disclosed |
| US-20060193786-A1 | Pharmaceutical composition for intranasal administration containing a CGRP antagonist | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
| US-20050032783-A1 | Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-10 | — | — | US | disclosed |
| EP-1207884-B1 | USE OF CGRP ANTAGONISTS AND CGRP RELEASE INHIBITORS FOR CONTROLLING MENOPAUSAL HOT FLASHES | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-11-03 | — | — | EP | disclosed |
| US-20040076587-A1 | Pharmaceutical composition for intranasal administration containing a CGRP antagonist | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-04-22 | — | — | US | disclosed |
| US-6521609-B1 | Using such as amino acid derivatives or serotonin receptor agonists; side effect reduction | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050233980-A1 | CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine | SLC6A4, SLC6A2, HTR3B | CALCRL 26/4885CYP3A4 2585/4885RAMP1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.